| Scott D Mclaren, MD | |
|
929 N Saint Francis Ave, Wichita, KS 67214 | |
| (316) 268-5000 | |
| Not Available |
| Full Name | Scott D Mclaren |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 929 N Saint Francis Ave, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013145572 | NPI | - | NPPES |
| 2014018782 | Other | MO | LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kansas Surgery & Recovery Center | Wichita, KS | Hospital |
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Via Christi Hospitals Wichita Inc | 5799696944 | 70 |
| Anesthesia Consulting Services, Pa | 7214849710 | 77 |
News Archive
Graft size, sex and age have a significant effect on the odds of an ACL re-tear post reconstruction with a hamstring graft, say researchers presenting their work today at the American Orthopaedic Society of Sports Medicine's (AOSSM) Annual Meeting in Colorado Springs, CO.
A team of researchers from the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, from the Tumour Suppression Group, together with scientists from London and Santiago de Compostela, has discovered that the cellular reprogramming gene SOX2, which is involved in several types of cancers, such as lung cancer and pituitary cancer, is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with these types of cancer.
U.S. women are largely unaware of uterine fibroid embolization (UFE), a minimally invasive treatment for uterine fibroids that is less painful, preserves the uterus and allows women to get back to their lives sooner than surgical options, according to results from a new nationwide poll released today by the Society of Interventional Radiology.
Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.
Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.
› Verified 9 days ago
| Entity Name | Anesthesia Consulting Services, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518070416 PECOS PAC ID: 7214849710 Enrollment ID: O20031113000271 |
News Archive
Graft size, sex and age have a significant effect on the odds of an ACL re-tear post reconstruction with a hamstring graft, say researchers presenting their work today at the American Orthopaedic Society of Sports Medicine's (AOSSM) Annual Meeting in Colorado Springs, CO.
A team of researchers from the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, from the Tumour Suppression Group, together with scientists from London and Santiago de Compostela, has discovered that the cellular reprogramming gene SOX2, which is involved in several types of cancers, such as lung cancer and pituitary cancer, is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with these types of cancer.
U.S. women are largely unaware of uterine fibroid embolization (UFE), a minimally invasive treatment for uterine fibroids that is less painful, preserves the uterus and allows women to get back to their lives sooner than surgical options, according to results from a new nationwide poll released today by the Society of Interventional Radiology.
Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.
Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.
› Verified 9 days ago
| Entity Name | Ascension Via Christi Hospitals Wichita Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589333 PECOS PAC ID: 5799696944 Enrollment ID: O20031118000404 |
News Archive
Graft size, sex and age have a significant effect on the odds of an ACL re-tear post reconstruction with a hamstring graft, say researchers presenting their work today at the American Orthopaedic Society of Sports Medicine's (AOSSM) Annual Meeting in Colorado Springs, CO.
A team of researchers from the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, from the Tumour Suppression Group, together with scientists from London and Santiago de Compostela, has discovered that the cellular reprogramming gene SOX2, which is involved in several types of cancers, such as lung cancer and pituitary cancer, is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with these types of cancer.
U.S. women are largely unaware of uterine fibroid embolization (UFE), a minimally invasive treatment for uterine fibroids that is less painful, preserves the uterus and allows women to get back to their lives sooner than surgical options, according to results from a new nationwide poll released today by the Society of Interventional Radiology.
Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.
Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott D Mclaren, MD Po Box 2897, Wichita, KS 67201-2897 Ph: (844) 468-9498 | Scott D Mclaren, MD 929 N Saint Francis Ave, Wichita, KS 67214 Ph: (316) 268-5000 |
News Archive
Graft size, sex and age have a significant effect on the odds of an ACL re-tear post reconstruction with a hamstring graft, say researchers presenting their work today at the American Orthopaedic Society of Sports Medicine's (AOSSM) Annual Meeting in Colorado Springs, CO.
A team of researchers from the Spanish National Cancer Research Centre (CNIO), led by Manuel Serrano, from the Tumour Suppression Group, together with scientists from London and Santiago de Compostela, has discovered that the cellular reprogramming gene SOX2, which is involved in several types of cancers, such as lung cancer and pituitary cancer, is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with these types of cancer.
U.S. women are largely unaware of uterine fibroid embolization (UFE), a minimally invasive treatment for uterine fibroids that is less painful, preserves the uterus and allows women to get back to their lives sooner than surgical options, according to results from a new nationwide poll released today by the Society of Interventional Radiology.
Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.
Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.
› Verified 9 days ago
James Phillips, Anesthesiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St Ste 3023, Wichita, KS 67214 Phone: 316-293-2665 | |
Valerie Audra Grau, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-268-5000 | |
John Dale Peterson, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 929 N Saint Francis St, Wichita, KS 67214 Phone: 800-374-5326 Fax: 800-374-7656 | |
Dylan Michael Brittain, DO Anesthesiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Jonathan Michael Snell, DO Anesthesiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Michael A Mueller, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 8080 E Central Ave, Ste 250, Wichita, KS 67206 Phone: 316-686-7327 Fax: 316-686-1557 |